Altimmune, Inc.

📍 Gaithersburg, United States🗓 Founded 1997👥 66 employees💰 Last funded Mar 2023
Biotechnology Research🌐 altimmune.com
Website LinkedIn
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
1997
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Sweden
1
United States
1
Frequently asked questions
Who invested in Altimmune, Inc.?
Altimmune, Inc. has 2 investors on record on gritt.io.
When did Altimmune, Inc. last raise funding?
The most recent investment in Altimmune, Inc. recorded on gritt.io was in March 2023.
When was Altimmune, Inc. founded?
Altimmune, Inc. was founded in 1997.
What industry is Altimmune, Inc. in?
Altimmune, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Altimmune, Inc. based?
Altimmune, Inc. is headquartered in Gaithersburg, United States.